Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Aprea Therapeutics
Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
September 25, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
September 09, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
September 09, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
August 28, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
June 21, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
June 17, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
May 28, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
May 14, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
May 13, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 02, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
April 10, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
March 26, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
March 11, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
March 11, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
March 05, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
February 06, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
January 30, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
January 04, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
November 09, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
October 24, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
October 16, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
August 24, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
August 10, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference
June 14, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics to Present at BIO International Convention
May 30, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
May 15, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors
May 08, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations
March 30, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
March 16, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.